The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.00
Bid: 308.00
Ask: 308.50
Change: 14.50 (4.97%)
Spread: 0.50 (0.162%)
Open: 298.00
High: 308.00
Low: 285.50
Prev. Close: 291.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

14 Oct 2020 07:00

RNS Number : 9815B
Synthomer PLC
14 October 2020
 

October 14th 2020

 

Synthomer plc

 

Q3 Trading Update

 

FY2020 EBITDA guidance raised 10%, interim dividend reinstated and pro forma leverage expected to reduce to circa 2.0x EBITDA by end of 2020

 

Synthomer plc ("Synthomer" or "the Group") today brings forward its update on trading for the third quarter ("Q3") ended September 30th 2020.

 

Strong trading momentum across all three business divisions

 

Performance Elastomers volumes and margins are ahead of prior year reflecting strong demand in Nitrile Latex following the COVID-19 pandemic and improved conditions in SBR latex through Q3.

 

Functional Solutions continued to benefit from the integration of OMNOVA and likewise is trading ahead of prior year albeit some market sectors are demonstrating stronger resilience than others. End market and geographic diversification remains a key strength of our Functional Solutions business.

 

Industrial Specialities continued to improve in Q3 following a weaker Q2 impacted by COVID-19. Current run rate volumes and margins are on or above prior year.

 

FY EBITDA guidance raised 10%

 

At the time of its Interim Results in August, the Group said that it expected FY 2020 EBITDA to be broadly-in-line with market consensus of £211 million (source Teneo). Synthomer now expects FY 2020 EBITDA to be circa £232 million, 10% higher than where it was envisaged to be in August.

 

Proforma leverage expected to reduce to circa 2.0x EBITDA

 

The Group remains highly cash generative and now expects proforma leverage to reduce to circa 2.0x net debt to EBITDA by December 2020.

 

Interim dividend reinstated

 

As a result of the Group's strong trading performance and cash generation, the Board has decided to reinstate the interim dividend which was suspended in April. The Board has declared an interim dividend of 3.0 pence per share payable on November 10th 2020 to shareholders on the register at close of business on October 23rd 2020. The Board has also fully reinstated its existing dividend policy and intends to pay a final dividend in line with its capital policy.

 

Further strategic progress

 

The integration of OMNOVA is proceeding ahead of schedule. As previously stated, the Group now expects synergies to achieve a $20 million run rate by the end of year (increased from $15 million) and a $40 million run rate by the end of 2022 (increased from $30 million).

 

In August, the Group confirmed that it was in a consultation process with employees at its SBR site in Oulu (Finland) concerning future options for the site. The consultation process at Oulu is complete and the decision has been made to close this site by the end of Q1 2021. Consultations are continuing at Marl (Germany) with an outcome expected in Q4 this year. Synthomer remains committed to the SBR markets in Europe and is confident of being able to service customers from its Central European asset base. 

 

Our additional Nitrile Latex capacity in Malaysia is on schedule for beneficial operation in Q4 2021 to further support the strong demand we have seen following the COVID-19 pandemic.

 

 

Calum MacLean, Chief Executive of Synthomer said:

 

"This is a very encouraging performance with all business divisions performing ahead of prior year. Alongside this strong momentum, we have made significant strategic progress, with a decision to close our site in Oulu and the integration of OMNOVA continuing ahead of our initial expectations. This underpins our confidence for the remainder of this year and beyond leading to an upgrade to our guidance for the full year and reinstating our interim dividend."

 

 

Further information:

 

The Company will hold a conference call for investors and analysts at 0900 BST today:

Dial in number: 08003589473 PIN: 69896742#

 

 

Calum MacLean, Chief Executive Officer

 

Steve Bennett, Chief Financial Officer

Tel: + 44 1279 436211

Tim Hughes, President, Corporate Development

 

 

 

Charles Armitstead/ Matt Denham, Teneo

Tel: + 44 7703 330 269/ + 44 7825 735596

 

 

Investor Seminar

Synthomer will be hosting an Investor Seminar on Wednesday 18th November to focus on the Group's strategy post its acquisition of OMNOVA, with a particular focus on its Functional Solutions business.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOVBRRUURAAA
Date   Source Headline
30th Jul 20197:00 amRNSResults of Rights Issue
26th Jul 20192:48 pmRNSDirector/PDMR Shareholding
26th Jul 20192:46 pmRNSDirector/PDMR Shareholding
24th Jul 20194:34 pmRNSDirector Declaration
15th Jul 20197:00 amRNSAdmission of Nil Paid Rights
10th Jul 20191:49 pmRNSPublication of Circular and Prospectus
10th Jul 20191:34 pmRNSDirector/PDMR Shareholding
3rd Jul 20197:00 amRNSAcquisition
2nd Jul 20193:56 pmRNSDirector Declaration
13th Jun 201911:18 amRNSDirector Declaration
25th Apr 20194:45 pmRNSResult of AGM
25th Apr 20197:00 amRNSQ1 Trading Update
10th Apr 20194:51 pmRNSDirector/PDMR Shareholding
10th Apr 20194:50 pmRNSDirector/PDMR Shareholding
10th Apr 20194:43 pmRNSDirector/PDMR Shareholding
10th Apr 20194:41 pmRNSDirector/PDMR Shareholding
28th Mar 20193:51 pmRNSDirector/PDMR Shareholding
28th Mar 20193:50 pmRNSDirector/PDMR Shareholding
25th Mar 20193:15 pmRNSAnnual Financial Report
21st Mar 20193:39 pmRNSDirector Declaration
18th Mar 201910:02 amRNSDirector/PDMR Shareholding
12th Mar 201911:25 amRNSDirector/PDMR Shareholding
12th Mar 201911:23 amRNSDirector/PDMR Shareholding
5th Mar 20194:09 pmRNSDirector/PDMR Shareholding
4th Mar 20197:00 amRNSResults for the year ended 31 December 2018
1st Mar 20193:26 pmRNSDirector Declaration
3rd Dec 201810:54 amRNSHolding(s) in Company
9th Nov 201811:36 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSQ3 Trading update
17th Oct 20189:29 amRNSDirector Declaration
21st Sep 20189:17 amRNSDirectorate Change
6th Aug 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20186:25 pmRNSDirector/PDMR Shareholding
10th Jul 20189:47 amRNSHolding(s) in Company
4th Jul 201811:45 amRNSHolding(s) in Company
4th Jul 201811:44 amRNSHolding(s) in Company
4th Jul 201811:43 amRNSHolding(s) in Company
28th Jun 20183:12 pmRNSUpdate on Proposed Offering
25th Jun 20187:19 amRNSPROPOSED OFFERING OF EUR300M BOND & REFINANCING
21st Jun 201810:16 amRNSResult of Extraordinary General Meeting
8th Jun 20187:00 amRNSEuropean Commission investigation
4th Jun 20181:02 pmRNSNotice of GM
3rd May 20181:38 pmRNSHolding(s) in Company
2nd May 20184:29 pmRNSDirector/PDMR Shareholding
26th Apr 20182:23 pmRNSResult of AGM
26th Apr 20187:00 amRNSQ1 Trading update
9th Apr 20184:54 pmRNSDirector Declaration
27th Mar 20181:03 pmRNSDirector/PDMR Shareholding
27th Mar 20181:01 pmRNSDirector/PDMR Shareholding
26th Mar 20184:55 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.